Get started

Trend Line Break

NIFTY DAILY - 13/3/2024Nifty open with gap up opening and bulls didn’t survive in the market and bear took control and made days low that is 21905 level. Nifty has broken the trend line support and formed a red big candle with upper and lower shadow. MACD is giving Crossdown. 90% of the candle is below the 9 days Exponential Moving Average line. Index has broken the support level which was 22272 so, further support will be 21791 level with resistance of 22115 level. Today’s Advance Decline ratio of NIFTY50 Advance - 6 Decline - 43 FII Sell – 4595.06 crore DII Buy +9093.72 crore ⚠️ Important: Always maintain your Risk & Reward Ratio. ✅Like and follow to never miss a new idea!✅ Disclaimer: I am not SEBI Registered Advisor. My posts are purely for training and educational purposes. Eat🍜 Sleep😴 TradingView📈 Repeat 🔁 Happy learning with trading. Cheers!🥂
NSE:NIFTY
by radha_23
TVS Motors, Buy on Weekly charts!Price has broken out of a nice consolidation and if it does a minor retracement and then creates a strong bullish candle, it will be a good buying opportunity. Stoploss would be below the previous resistance and trailing stoploss can be below 20EMA. Alternatively ATR can also be used to determine trailing stoploss, it all depends on what you are comfortable with. That said, as usual, please pay attention to position sizing and manage your risk wisely.
NSE:TVSMOTORLong
by Amit_Thakkar_
IBULHSGFIN : Strong 200 EMA Breakout#IBULHSGFIN #breakout #trendlinebreakout #200emabreakout #swingtrade IBULHSGFIN : Strong 200 EMA Breakout >> Trendline Breakout soon >> Good Strength & Decent Volumes >> Trending Stock & in Momentum >> Low Risk High Reward Trade Swing Traders can Lock profit at 10% & keep trailing Please give a Boost or comment if u r Liking the analysis & Learning from it. Keep showing ur Love by following Disclaimer : This is not a Trade Recommendations & Charts/ stocks Mentioned are for Learning/Educational Purpose. Do your Own Analysis before Taking positions.
ILong
by moneyfesttrading
#MaxHealth is getting ready to heal the pain #SuperChartzKey Levels: Support: 830 Closing Basis Resistance: 900, 999, 1099 Key Drivers: Max Healthcare Institute Limited, India's second-largest hospital chain, offers a diverse array of healthcare services, including complex procedures like transplants, robotic surgeries, cardiac, neuro, orthopedic, and oncology surgeries. They have 17 facilities with a current capacity of ~3,530 beds, boasting a ~75% occupancy rate. Their Max Lab has 435+ partner-run CCs, 23 CoCCs, and ~170 PAS. Max@Home conducts 3,000+ daily billed transactions and has 14 specialized services. Max MyHealth, their digital platform, accounted for ~21% of H1FY24 revenues. They have significant strategic partnerships with Deakin University and Imperial College London, with ~1,000 high-index journal research publications in the last 5 years and 500 completed clinical research projects. Max recently acquired 550 bedded Sahara Hospital for ~Rs. 940 crs and aims to double its bed capacity with a planned brownfield expansion of ~2600 beds and potential to add 1,000 beds through land parcels. They plan to add beds in NCR as follows: FY24: 300 beds for Rs. 918 crs, FY25: 819 beds for Rs. 1592 crs, FY26: 1100 beds for Rs. 1377 crs, FY27: 521 beds for Rs. 552 crs, FY28: 1350 beds. The company has a significant market capitalization of ₹84,041 Cr, with its current stock price at ₹865, fluctuating between a high of ₹910 and a low of ₹412. Its price-to-earnings ratio (P/E) stands high at 79.5, indicating investor optimism. The book value per share is ₹80.7, and the dividend yield is 0.12%. It maintains healthy returns with ROCE at 15.0% and ROE at 16.1%. The operating profit margin (OPM) is robust at 27.9%. The company's EPS is ₹10.9, and it demonstrates strong performance compared to the industry with a return over three months at 39.4% and return over three years at 65.2%. The return on assets is 11.4%, showcasing efficient asset utilization. It generated significant sales of ₹5,198 Cr. The enterprise value is ₹82,910 Cr, with an EVEBITDA ratio of 51.0. The debt-to-equity ratio is low at 0.08, reflecting a healthy financial structure. Overall, the company exhibits strong financials, profitability, and market performance.
NSE:MAXHEALTHLong
by SuperChartz